Genmab A/S (GMAB) News Today $20.59 -0.59 (-2.79%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy NowNovember 15 at 4:45 PM | msn.comCrossmark Global Holdings Inc. Has $932,000 Stake in Genmab A/S (NASDAQ:GMAB)Crossmark Global Holdings Inc. reduced its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 45.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,245 shares of the company's stock after selling 32,387 sharesNovember 15 at 3:43 AM | marketbeat.comLeerink Partnrs Predicts Stronger Earnings for Genmab A/SNovember 11, 2024 | americanbankingnews.comLeerink Partnrs Forecasts Increased Earnings for Genmab A/SGenmab A/S (NASDAQ:GMAB - Free Report) - Stock analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for Genmab A/S in a report issued on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now expects that the company will earn $1.29 per share for the year, up from thNovember 11, 2024 | marketbeat.comGenmab A/S (GMAB) Q3 2024 Earnings Conference Call TranscriptNovember 9, 2024 | seekingalpha.comGenmab A/S 2024 Q3 - Results - Earnings Call PresentationNovember 9, 2024 | seekingalpha.comGenmab A/S (NASDAQ:GMAB) Receives "Outperform" Rating from BMO Capital MarketsBMO Capital Markets reaffirmed an "outperform" rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a report on Friday.November 8, 2024 | marketbeat.comFY2024 EPS Estimates for Genmab A/S Boosted by William BlairGenmab A/S (NASDAQ:GMAB - Free Report) - Equities research analysts at William Blair upped their FY2024 earnings per share estimates for Genmab A/S in a report issued on Wednesday, November 6th. William Blair analyst M. Phipps now anticipates that the company will post earnings of $1.24 per shareNovember 8, 2024 | marketbeat.comGenmab’s Revenue Soars with Strategic DevelopmentsNovember 7, 2024 | markets.businessinsider.comGenmab A/S: Genmab Announces Financial Results for the First Nine Months of 2024November 6, 2024 | finanznachrichten.deGenmab Revenue Surges 18% in Q3November 6, 2024 | fool.comGenmab Announces Financial Results for the First Nine Months of 2024November 6, 2024 | globenewswire.comGenmab: Looking To Manage My Position Around Q3 EarningsNovember 6, 2024 | seekingalpha.comGenmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume - Should You Buy?Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase - Time to Buy?November 5, 2024 | marketbeat.comGenmab to Present at Jefferies London Healthcare ConferenceNovember 5, 2024 | globenewswire.comGenmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual MeetingNovember 5, 2024 | businesswire.comGenmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual MeetingNovember 5, 2024 | globenewswire.comUS Bancorp DE Has $4.19 Million Holdings in Genmab A/S (NASDAQ:GMAB)US Bancorp DE boosted its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 16.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 171,669 shares of the company's stock after buying an aNovember 5, 2024 | marketbeat.comCreative Planning Purchases 27,353 Shares of Genmab A/S (NASDAQ:GMAB)Creative Planning raised its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 136.3% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 47,422 shares of the company's stock after purchasing an additional 27,353 shaNovember 1, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Reaches New 1-Year Low - Time to Sell?Genmab A/S (NASDAQ:GMAB) Reaches New 12-Month Low - Time to Sell?October 31, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from BrokeragesGenmab A/S (NASDAQ:GMAB - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twelve research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendOctober 31, 2024 | marketbeat.comGenmab A/S (GMAB) Set to Announce Quarterly Earnings on WednesdayGenmab A/S (NASDAQ:GMAB) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=641006)October 30, 2024 | marketbeat.comMediolanum International Funds Ltd Buys Shares of 28,661 Genmab A/S (NASDAQ:GMAB)Mediolanum International Funds Ltd bought a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 28,661 shares of the company's stock, valued at approximately $699,000. Several other large inOctober 28, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Hits New 52-Week Low - What's Next?Genmab A/S (NASDAQ:GMAB) Hits New 52-Week Low - What's Next?October 22, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Sees Large Volume Increase - Here's What HappenedGenmab A/S (NASDAQ:GMAB) Sees Unusually-High Trading Volume - Time to Buy?October 21, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for Genmab A/S Q3 Earnings?Genmab A/S (NASDAQ:GMAB - Free Report) - Research analysts at HC Wainwright lowered their Q3 2024 earnings per share (EPS) estimates for shares of Genmab A/S in a note issued to investors on Wednesday, October 16th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.34 pOctober 21, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC trimmed its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 60.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,447 shares of the company's stock after selling 21,787 shareOctober 19, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a report on Wednesday.October 16, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Reaches New 52-Week Low - Here's What HappenedGenmab A/S (NASDAQ:GMAB) Sets New 1-Year Low - Here's WhyOctober 15, 2024 | marketbeat.comGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024October 15, 2024 | globenewswire.com12 Most Profitable Growth Stocks To Invest InOctober 13, 2024 | insidermonkey.comMorgan Stanley Remains a Hold on Genmab (GMAB)October 11, 2024 | markets.businessinsider.comAssessing Genmab’s Financial Outlook Amidst Darzalex Market Challenges and Patent Expiry ConcernsOctober 11, 2024 | markets.businessinsider.comSanctuary Advisors LLC Takes Position in Genmab A/S (NASDAQ:GMAB)Sanctuary Advisors LLC acquired a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 53,893 shares of the company's stock, valued at approximOctober 11, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Sold by Millennium Management LLCMillennium Management LLC reduced its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 19.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 380,995 shares of the company's stock after sellinOctober 9, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Given Consensus Recommendation of "Hold" by BrokeragesGenmab A/S (NASDAQ:GMAB - Get Free Report) has been given an average recommendation of "Hold" by the thirteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendationOctober 6, 2024 | marketbeat.comMajor Shareholder AnnouncementOctober 4, 2024 | globenewswire.comIs Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?September 30, 2024 | msn.comMarshall Wace LLP Sells 301,046 Shares of Genmab A/S (NASDAQ:GMAB)Marshall Wace LLP lessened its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 31.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 648,379 shares of the company's stock after selling 30September 28, 2024 | marketbeat.comOpenAI chair says board has discussed equity compensation for CEO Sam AltmanSeptember 27, 2024 | ca.finance.yahoo.comGenmab A/S (NASDAQ:GMAB) Shares Acquired by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC lifted its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 109.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 278,541 shares of the company's stock after purchasinSeptember 27, 2024 | marketbeat.comGrant of Restricted Stock Units and Warrants to Employees in GenmabSeptember 26, 2024 | globenewswire.comDenmark shares lower at close of trade; OMX Copenhagen 20 down 1.42%September 24, 2024 | msn.comDenmark stocks lower at close of trade; OMX Copenhagen 20 down 1.42%September 24, 2024 | msn.comGenmab A/S (NASDAQ:GMAB) Sets New 52-Week Low at $24.36Genmab A/S (NASDAQ:GMAB) Reaches New 12-Month Low at $24.36September 23, 2024 | marketbeat.comEnvestnet Asset Management Inc. Lowers Stake in Genmab A/S (NASDAQ:GMAB)Envestnet Asset Management Inc. lowered its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 2.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 995,667 shares of the company's stock after selling 26,463 shaSeptember 22, 2024 | marketbeat.comBuy Rating Affirmed for Genmab on RYBREVANT Approval and Promising Pipeline ValuationSeptember 20, 2024 | markets.businessinsider.comGenmab A/S's (GMAB) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Friday.September 20, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Stake Boosted by Renaissance Technologies LLCRenaissance Technologies LLC raised its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 7.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,462,459 shares of the company's stock after buSeptember 19, 2024 | marketbeat.comAcadian Asset Management LLC Purchases 29,762 Shares of Genmab A/S (NASDAQ:GMAB)Acadian Asset Management LLC raised its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 360.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,010 shares of the company's stock after buyinSeptember 17, 2024 | marketbeat.com Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address The only candlestick pattern worth a darn (Ad)It’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again… Follow this link here and enter your email address to sign up… GMAB Media Mentions By Week GMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMAB News Sentiment▼0.960.55▲Average Medical News Sentiment GMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMAB Articles This Week▼95▲GMAB Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today BioNTech News Today Teva Pharmaceutical Industries News Today BeiGene News Today Viatris News Today Moderna News Today Summit Therapeutics News Today Dr. Reddy's Laboratories News Today Vaxcyte News Today Catalent News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMAB) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
